Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.379,91 +827,75 (+2,20%) EUR/USD
1,0708 +0,0003 (+0,03%) Bitcoin EUR
62.597,80 +679,57 (+1,10%) CMC Crypto 200
1.438,02 +23,26 (+1,64%)
Incyte Corporation (0J9P.L)
- GlobeNewswire
Global CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
- GlobeNewswire
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
